Investors Show Increased Interest in TG Therapeutics (NASDAQ:TGTX) Call Options

TG Therapeutics, Inc. (NASDAQ:TGTX) experienced a significant rise in options trading on Monday, as investors purchased a total of 13,927 call options. This volume represents a remarkable increase of about 105% compared to the average daily transactions of 6,778 call options. Such unusual trading activity often draws attention from analysts and investors alike.

Recent Insider Activity at TG Therapeutics

In related developments, the company’s Chief Financial Officer, Sean A. Power, conducted a transaction on January 3rd, where he sold 11,337 shares of TG Therapeutics stock. The shares were sold at an average price of $30.29, amounting to a total of approximately $343,398. After this sale, Power retains ownership of 670,632 shares, valued at around $20.31 million. This transaction reflects a 1.66% decrease in his ownership position. Notably, insider ownership in the company stands at 10.50%.

Institutional Investment Trends in TG Therapeutics

Recently, several institutional investors have made adjustments to their holdings of TG Therapeutics. State Street Corp increased its share ownership by 35.8% in the third quarter, now holding 9,094,158 shares, valued at roughly $212.71 million, following the acquisition of an additional 2,398,015 shares. Clearbridge Investments LLC also made a noteworthy addition by purchasing a new stake valued at about $55.24 million during the fourth quarter. Meanwhile, Principal Financial Group Inc. raised its stake dramatically by 1,549.4% in the same quarter, now owning 772,188 shares worth approximately $18.06 million. Other hedge funds including Raymond James Financial and Braun Stacey Associates made significant investments as well. Collectively, institutional investors hold 58.58% of TG Therapeutics stock.

Insights from Wall Street Analysts

Several analysts have recently analyzed TG Therapeutics. StockNews.com downgraded TG Therapeutics from a "hold" to a "sell" rating on January 31st. Conversely, The Goldman Sachs Group adjusted their price target from $20.00 to $22.00 while maintaining a "neutral" rating. JPMorgan Chase & Co. made optimistic revisions by raising their price target from $30.00 to $43.00, affirming an "overweight" rating. HC Wainwright issued a "buy" rating alongside a price target of $55.00. Currently, one analyst rates the stock as a sell, one as a hold, and five analysts give it a buy rating, leading to a consensus rating of "Moderate Buy" with an average target price set at $40.67.

TG Therapeutics Stock Performance Insights

On Monday, TG Therapeutics stock rose by $4.69, reaching a trading price of $34.78 during midday sessions. The trading volume hit 5,251,303 shares, surpassing the average volume of 2,224,063. The fifty-day moving average stands at $30.75, while the two-hundred day moving average is $28.14. The company has a market capitalization of $5.41 billion and a price-to-earnings ratio of -341.12, with a beta value of 2.26. TG Therapeutics recorded a one-year low of $12.93 and a one-year high of $36.84. The latest earnings report from the company indicated earnings per share (EPS) of $0.15 for the quarter, exceeding the consensus expectation of $0.09.

About TG Therapeutics

TG Therapeutics, Inc. is engaged in the acquisition, development, and commercialization of innovative treatments for B-cell mediated diseases, both domestically and internationally. The company is notably known for BRIUMVI, an anti-CD20 monoclonal antibody developed for adult patients suffering from relapsing forms of multiple sclerosis (RMS), including relapsing-remitting disease and secondary progressive disease.

investment, stocks, options